

(Use several sheets if necessary)

Sheet 1 of 2

ATTY. DOCKET NO.
33564-US-PC
APPLICATION NO.

Not Yet Known

APPLICANT

BODNAY, ET AL.

FILING DATE

APR 21 2007

19 JUN 2006

Herewith

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
AM	02/46471	6/13/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
AN	2004/020582	3/11/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
AO	03/034067	4/24/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/M.N./	AR	Neshat et al., "Enhanced Sensitivity of PTEN-Deficient Tumors to Inhibition of FRAP/mTOR", Proceedings of the National Academy of Sciences of the United States of America", Vol. 98, No. 18, pp. 10314-10319 (2001).
/M.N./	AS	Hidalgo et al, "The Rapamycin-Sensitive Signal Transduction Pathway as a Target for Cancer Therapy", Oncogene, Vol. 19, No. 56, pp. 6680-6686 (2000) -- Abstract.
/M.N./	AT	Kwiatkowski et al., "A Mouse Model of TSC1 Reveals Sex-Dependent Lethality from Liver Hemangiomas, and Up-Regulation of p70S6 Kinase Activity in Tsc1 Null Cells", Human Molecular Genetics, Vol. 11, No. 5, pp. 525-534 (2002) -- Abstract.

EXAMINER	/Meera Natarajan/	DATE CONSIDERED
----------	-------------------	-----------------

10/30/2007

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 2 of 2

ATTY. DOCKET NO.
33564-US-BCT
APPLICATION NO.
Not Yet Known
APPLICANT
BOULAY ET AL
FILING DATE
10/15/2007
Herewith10/15/2007
10/19 JUN 2006

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/M.N./	BA	Shi et al., "Enhanced Sensitivity of Multiple Myeloma Cells Containing PTEN Mutations to CCI-779", Cancer Research, Vol. 62, No. 17, pp. 5027-5034 (pp. 2002).
/M.N./	BB	Huang et al., "Resistance to Rapamycin: A Novel Anticancer Drug", Cancer and Metastasis Reviews, Vol. 20, No. 1-2, pp. 69-78 -- Abstract.
/M.N./	BC	Fukazawa et al., "Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase (MEK) Inhibitors Restore Anoikis Sensitivity in Human Breast Cancer Cell Lines with a Constitutively Activated...", Molecular Cancer Therapeutics, Vol. 1, No. 5, pp. 303-309 (2002) -- Abstract.
/M.N./	BD	Dumont et al., "Mechanism of Action of the Immunosuppressant Rapamycin", Life Sciences, Vol. 58, No. 5, pp. 373-395 -- Abstract.
	BE	
	BF	
	BG	
	BH	
	BI	
	BJ	
	BK	
	BL	
	BM	
	BN	

EXAMINER

/Meera Natarajan/

DATE CONSIDERED

10/30/2007

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.